Embolx
Sunnyvale, US · Founded 2013 · 1 known investors
Embolx is a commercial-stage medical device company developing microcatheters for arterial embolization procedures used to treat conditions such as cancerous tumors, benign prostatic hyperplasia, and uterine fibroids. Its Sniper balloon occlusion microcatheter controls blood flow pressure to direct embolic delivery to target tissue while protecting surrounding tissue.
Founders & leadership
MA
MICHAEL ALLENPresident & Chief Executive Officer
MP
Michael P. AllenExecutive
RJ
Robert J.J. de NeveExecutive
MA
Michael AllenPresident & CEO
NG
NORMAN GITISNamed on SEC filing
PR
PAUL ROGANNamed on SEC filing
FG
FRANK GRILLONamed on SEC filing
TX
TIANHONG XUNamed on SEC filing
TB
TOM BRETONManager of Research & Development
ML
MICHAEL LINDirector of Finance
Board
PF
Paul F. RoganBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 4 rounds · 2014–2022
▶$1.6MraisedNov 2022 · 5 investors · OtherRule 506(b)
▶$1.6MraisedNov 2022 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- NORMAN GITISDirector
- PAUL ROGANDirector
- TOM BRETONExecutive Officer
- FRANK GRILLODirector
- MICHAEL ALLENExecutive Officer, Director
- TIANHONG XUDirector
- MICHAEL LINExecutive Officer
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- Sales commissions
- $130.3K
- Placement agents
- Revere Securities LLC
- First sale
- Oct 2022
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$250KraisedMay 2014 · 1 investors · OtherRule 506(b)
▶$250KraisedMay 2014 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michael P. AllenExecutive Officer, Director
- Paul F. RoganDirector
- Robert J.J. de NeveExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $250K
- First sale
- May 2014
- Incorporated
- Corporation, California, 2013
- Federal exemptions
- 06b, 04.3, 4a5
▶$662raisedMar 2014 · 3 investors · OtherRule 506(b)
▶$662raisedMar 2014 · 3 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michael P. AllenExecutive Officer, Director
- Paul F. RoganDirector
- Robert J.J. de NeveExecutive Officer, Director
- Offering amount
- $662
- Amount sold
- $662
- First sale
- Feb 2014
- Incorporated
- Corporation, California, 2013
- Federal exemptions
- 06b, 04.3, 4a5
▶$250KraisedMar 2014 · 1 investors · OtherRule 506(b)
▶$250KraisedMar 2014 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Michael P. AllenExecutive Officer, Director
- Robert J.J. de NeveExecutive Officer, Director
- Paul F. RoganDirector
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Feb 2014
- Incorporated
- Corporation, California, 2013
- Federal exemptions
- 06b, 04.3, 4a5
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBoston Scientific18 shared keywordsBoston Scientific supports external researcher-initiated studies through its Investigator Sponsored Research program, which funds independent investigations addressing disease understanding and treatment gaps of interest to the medical community.
Merit Medical12 shared keywordsMerit Medical Systems designs, develops, manufactures and markets medical devices for interventional and diagnostic procedures. The company serves healthcare providers and clinical practitioners in the medical device industry.
Rf Surgical11 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Read the Press Release10 shared keywordsStryker is a medical technology company that develops and manufactures products across areas such as orthopaedics, surgical equipment, neurotechnology, and spine care for hospitals and healthcare providers. It operates globally across the Americas, Europe, Asia-Pacific, and the Middle East.
Companies competing with Embolx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Embolx do?
- Embolx is a commercial-stage medical device company developing microcatheters for arterial embolization procedures used to treat conditions such as cancerous tumors, benign prostatic hyperplasia, and uterine fibroids. Its Sniper balloon occlusion microcatheter controls blood flow pressure to direct embolic delivery to target tissue while protecting surrounding tissue.
- Who are Embolx's investors?
- Embolx's investors include BayMed Venture Partners.
- How much funding has Embolx raised?
- Embolx has disclosed $2.1M raised across 4 rounds.
- Where is Embolx headquartered?
- Embolx is headquartered in Sunnyvale, US.